Loading…
Antiproliferative effects of new magnetic pH-responsive drug delivery system composed of Fe 3 O 4 , CaAl layered double hydroxide and levodopa on melanoma cancer cells
In this study, an efficient drug delivery system composed of Fe O , CaAl layered double hydroxide (LDH) and l-Dopa has been synthesized through hydrogen bonds between l-Dopa and CaAl-LDH encapsulated Fe O nanoparticles (Fe O @CaAl-LDH@l-Dopa). The structural features of Fe O @CaAl-LDH@l-Dopa were ch...
Saved in:
Published in: | Materials science & engineering. C, Materials for biological applications Materials for biological applications, 2019-08, Vol.101, p.472 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | In this study, an efficient drug delivery system composed of Fe
O
, CaAl layered double hydroxide (LDH) and l-Dopa has been synthesized through hydrogen bonds between l-Dopa and CaAl-LDH encapsulated Fe
O
nanoparticles (Fe
O
@CaAl-LDH@l-Dopa). The structural features of Fe
O
@CaAl-LDH@l-Dopa were characterized using XRD, SEM, TEM, EDX, FT-IR, VSM, TGA, XPS, zeta potential analysis and BET. All of the characterization techniques show the uniform high surface area core-shell structure with about 120 nm in average size. Also, the obtained results clearly indicate that this drug delivery system possess high potent for adsorption of l-Dopa (52 wt%) and high drug encapsulation efficiency (71%). The amount of l-Dopa release in low pHs (53.8%) which simulates the environment of cancer cells is greater than higher pHs. The in vitro cytotoxic and anticancer activities of Fe
O
@CaAl-LDH@l-Dopa were investigated against Mel-Rm Cells Melanoma (NCIt: C3224) using LDH colorimetric assay and differential staining cell death assay. The results showed Fe
O
@CaAl-LDH@l-Dopa with a lower concentration of l-Dopa, illustrate a higher cytotoxicity and anticancer activity. |
---|---|
ISSN: | 1873-0191 |
DOI: | 10.1016/j.msec.2019.04.004 |